Skip to main content
Premium Trial:

Request an Annual Quote

Open Access and the Great IP Debate

Here's a story from the Columbia Spectator on a panel discussion of how intellectual property should be regulated. According to the article, John Sulston "[complained] that too much private funding tends to 'short circuit' research by subjugating scientific discovery to the short-term profit motive." Fellow panelist Harold Varmus got to stump for open access, "explaining that scientists’ collective obsession with publishing their work in prestigious journals has led to a biased system that only publicizes a small subset of useful scientific results," the article says. Varmus also noted that PLoS, which he cofounded, would be "fiscally self-sustaining" by 2010.

Want more? Over at his blog, Jonathan Eisen alerts readers that Varmus will be a guest on the Daily Show tonight.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.